AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2016
Dec 20, 2016
33651_dirs_2016-12-20_defb37ec-8674-425c-be26-f48f6a71efae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2016-10-25
Reporting Person: Knapp Thomas J (General Counsel)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-10-25 | Stock Option (right to buy) | $0.29 | A | 102000 | Acquired | 2026-10-25 | Common Stock (102000) | Direct |
Footnotes
F1: Granted pursuant to the Issuer's 2016 Incentive Plan.
F2: The Reporting Person obtained the securities pursuant to an Employment Agreement Amendment dated October 1, 2016. The securities were convertible into common stock at the rate of 1 share of common stock for each 1 stock option share, or an aggregate of 102,000 shares of common stock (pre-reverse stock split). The securities were converted into 5,100 stock options at a price of $5.744 per share (post-reverse split) as of November 14, 2016.
F3: This stock option vests in equal monthly installments beginning November 25, 2016 and ending March 31, 2017.